PIK3CA mutations often result in hyperactivation of the PI3K/AKT/mTOR pathway, which is associated with oncogenesis, tumor development, and resistance to endocrine therapy in HR‐positive, HER2‐negative ABC.21, 22, 23, 24, 25. The gene discussed is ERBB2; the disease is neoplasm.